Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Edition
European
US
Dermatology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Tralokinumab – Updates in Atopic Dermatitis
8
Mins
January 2026
A summary of new data on tralokinumab in atopic dermatitis, presented at conferences/symposia held between September and October 2024.
Read more
7
Mins
23 Nov 2023
Bimekizumab 3-Year Efficacy in Patients with Moderate-to-Severe Plaque Psoriasis: Response Maintenance, Re-treatment, and Effect on High-Impact Areas
Psoriasis symptoms can be not only uncomfortable, irritating, and painful, but can also impact several aspects of a patients’ daily life…
8
Mins
23 Nov 2023
Secukinumab for Patients with Moderate-to-Severe Hidradenitis Suppurativa: Post Hoc Analyses of Efficacy Endpoints, Draining Tunnels, Skin Pain, and Work Productivity
Due to the clinical heterogenicity of HS, assessment of disease severity is complex, and over 20 different outcome measures have…
2
Mins
23 Nov 2023
Efficacy and Safety of Upadacitinib in a Phase II Randomised, Double-Blind, Dose-Ranging Study of Adults with Extensive Non-segmental Vitiligo
Vitiligo is an autoimmune skin disorder that causes depigmentation of the skin and/or leukotrichia of the hair, resulting from the…
10
Mins
12 Oct 2023
Patient Centricity in Skin Treatments: Global Meeting of Experts in Dermatology
During this symposium, global experts in dermatology gave a series of lectures focused on skin treatments and their benefits for patients…
11
Mins
15 Jun 2023
Elevating Aesthetics: Patient-Specific Treatment with Hyaluronic Acid Fillers to Improve Appearance and Psychosocial Wellbeing
This review of the ‘Elevating Aesthetics’ symposium held at the International Master Course on Aging Science (IMCAS) 2023 shares insights…
11
Mins
14 Nov 2022
An Overview of the EORTC-CLTG 2022 Congress
This year’s European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Tumours Group (CLTG) Annual Meeting was held in Madrid, Spain. Presentations covered a broad range of topics in the field of cutaneous lymphomas, from molecular mechanisms, through diagnostics and prediction of prognosis, to skin-directed and targeted therapies, combination therapies, and patient-reported outcomes.
6
Mins
20 Oct 2022
Photoprotection and the Science Behind Skin Healing
Sun exposure can lead to tanning, but also to skin damage due to the actions of ultraviolet A and B, visible light, and infrared radiation. One result of sun exposure is field cancerisation (FC), the precursor to actinic keratosis (AK), which in turn is a risk factor for, most notably, squamous cell carcinoma.
6
Mins
20 Oct 2022
Clinical Efficacy and Outcomes of Remibrutinib (LOU064) in Patients with Chronic Spontaneous Urticaria Inadequately Controlled with H1-Antihistamines: Findings from a Phase IIb Study
Chronic spontaneous urticaria (CSU) is characterised by the spontaneous occurrence of wheals (hives) and/or angioedema for ≥6 weeks.1 CSU can persist for several years and is associated with severe pruritus. Skin mast cell activation in CSU occurs via Type I autoallergy driven by IgE to autoallergens, and a Type IIb autoimmune response due to mast cell-targeted autoantibodies against IgE or high-affinity IgE receptor.
Loading posts...
« Previous
1
2
3
4
…
12
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View